A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

• Status: Recruiting
• Trial end date: 2025-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline

• Have venous access sufficient to allow for blood sampling

• Are able to swallow oral medication

• Agree to skin biopsies

Exclusion Criteria:

• Have any other skin conditions, excluding plaque psoriasis

• Have a current or recent acute, active infection

• Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.

• Are lactating or breastfeeding women